M&A Deal Summary

Sun Pharma Acquires DUSA Pharmaceuticals

On December 20, 2012, Sun Pharma acquired medical products company DUSA Pharmaceuticals for 230M USD

Acquisition Highlights
  • This is Sun Pharma’s 4th transaction in the Medical Products sector.
  • This is Sun Pharma’s 4th largest (disclosed) transaction.
  • This is Sun Pharma’s 3rd transaction in the United States.
  • This is Sun Pharma’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2012-12-20
Target DUSA Pharmaceuticals
Sector Medical Products
Buyer(s) Sun Pharma
Deal Type Add-on Acquisition
Deal Value 230M USD
Advisor(s) Leerink Partners (Financial)
Reed Smith (Legal)

Target

DUSA Pharmaceuticals

Wilmington, Massachusetts, United States
DUSA Pharmaceuticals, Inc.® is a fully integrated specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® photodynamic therapy (PDT) technology platform used in conjunction with it’s proprietary light source, the BLU-U® Blue Light Photodynamic Therapy Illuminator.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Sun Pharma

Mumbai, India
Category Company
Founded 1983
Sector Life Science
Employees37,000
Revenue 477.6B INR (2024)
DESCRIPTION

Sun Pharma is a specialty generic pharmaceutical company. Products are sold through drug stores, mass merchants, grocery stores, and gift/specialty stores. Sun Pharma was founded in 1983 and is based in Mumbai, India.

DEAL STATS #
Overall 7 of 14
Sector (Medical Products) 4 of 5
Type (Add-on Acquisition) 2 of 7
State (Massachusetts) 1 of 3
Country (United States) 3 of 6
Year (2012) 1 of 1
Size (of disclosed) 4 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-02-23 Caraco Pharmaceutical Laboratories

Detroit, Michigan, United States

Caraco Pharmaceutical Laboratories Ltd. is a developer, manufacturer and marketer of generic drugs for the prescription and over-the-counter markets.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-04-04 Ranbaxy Laboratories

New Delhi, India

Ranbaxy Limited is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed and emerging 4 markets, many of which incorporate proprietary Novel Drug Delivery Systems and technologies developed at its own labs.

Buy $4.0B
Mergr

Product

Company

Legal